“Real-World Evidence Confirms Risk Stratification of the 31-GEP and i31-GEP in Prospectively Tested Patients With Stage I-III Cutaneous Melanoma ”. SKIN The Journal of Cutaneous Medicine 8, no. 2 (March 18, 2024): s386. Accessed October 14, 2025. https://skin.dermsquared.com/skin/article/view/2596.